Selected research
Industry Growth & Trends
Global Pet Cancer Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Pet Cancer Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Pet Cancer Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Pet Cancer Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pet Cancer Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Pet Cancer Therapeutics market include Zoetis, Zenoaq, VetiVax, VetDC, Inc, Rhizen Pharmaceutical SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, Ngelheim International GmbH and Morphogenesis, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Pet Cancer Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Pet Cancer Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pet Cancer Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pet Cancer Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Pet Cancer Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Pet Cancer Therapeutics Market by Company
Zoetis
Zenoaq
VetiVax
VetDC, Inc
Rhizen Pharmaceutical SA
Regeneus Ltd.
Oasmia Pharmaceuticals AB
Ngelheim International GmbH
Morphogenesis, Inc
Merial Inc
Karyopharm Therapeutics, Inc
ELIAS Animal Health
Elanco
Boehringer Ingelheim International GmbH
Aratana Therapeutics, Inc
AB Science
Pet Cancer Therapeutics Segment by Type
Immunotherapy
Combination Therapy
Chemotherapy
Targeted Therapy
Pet Cancer Therapeutics Segment by Application
Mammary
Squamous Cell Cancer
Lymphoma
Melanoma
Mast Cell Cancer
Others
Pet Cancer Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pet Cancer Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pet Cancer Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pet Cancer Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Pet Cancer Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Immunotherapy
- Combination Therapy
- Chemotherapy
- Targeted Therapy
Applications
- Mammary
- Squamous Cell Cancer
- Lymphoma
- Melanoma
- Mast Cell Cancer
- Others
Companies covered
- Zoetis
- Zenoaq
- VetiVax
- VetDC, Inc
- Rhizen Pharmaceutical SA
- Regeneus Ltd.
- Oasmia Pharmaceuticals AB
- Ngelheim International GmbH
- Morphogenesis, Inc
- Merial Inc
- Karyopharm Therapeutics, Inc
- ELIAS Animal Health
- Elanco
- Boehringer Ingelheim International GmbH
- Aratana Therapeutics, Inc
- AB Science
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Pet Cancer Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Pet Cancer Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Pet Cancer Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Pet Cancer Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Pet Cancer Therapeutics Market Size (2021-2032)
- 1.5.1 North America Pet Cancer Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Pet Cancer Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Pet Cancer Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Pet Cancer Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Pet Cancer Therapeutics Market Size Growth Rate (2021-2032)
2 Pet Cancer Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Immunotherapy
- 2.1.2 Combination Therapy
- 2.1.3 Chemotherapy
- 2.1.4 Targeted Therapy
- 2.2 Global Pet Cancer Therapeutics Market Size by Type
- 2.2.1 Global Pet Cancer Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Pet Cancer Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Pet Cancer Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Pet Cancer Therapeutics Market Size by Regions
- 2.3.1 North America Pet Cancer Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Pet Cancer Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Pet Cancer Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Pet Cancer Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Pet Cancer Therapeutics Market Size Breakdown by Type (2021-2026)
3 Pet Cancer Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Mammary
- 3.1.2 Squamous Cell Cancer
- 3.1.3 Lymphoma
- 3.1.4 Melanoma
- 3.1.5 Mast Cell Cancer
- 3.1.6 Others
- 3.2 Global Pet Cancer Therapeutics Market Size by Application
- 3.2.1 Global Pet Cancer Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Pet Cancer Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Pet Cancer Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Pet Cancer Therapeutics Market Size by Regions
- 3.3.1 North America Pet Cancer Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Pet Cancer Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Pet Cancer Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Pet Cancer Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Pet Cancer Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Pet Cancer Therapeutics Industry Trends
- 4.2 Pet Cancer Therapeutics Industry Drivers
- 4.3 Pet Cancer Therapeutics Industry Opportunities and Challenges
- 4.4 Pet Cancer Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Pet Cancer Therapeutics Revenue (2021-2026)
- 5.2 Global Pet Cancer Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Pet Cancer Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Pet Cancer Therapeutics Company, Product Type & Application
- 5.5 Global Pet Cancer Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Pet Cancer Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Pet Cancer Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Pet Cancer Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Zoetis
- 6.1.1 Zoetis Company Information
- 6.1.2 Zoetis Business Overview
- 6.1.3 Zoetis Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Zoetis Pet Cancer Therapeutics Product Portfolio
- 6.1.5 Zoetis Recent Developments
- 6.2 Zenoaq
- 6.2.1 Zenoaq Company Information
- 6.2.2 Zenoaq Business Overview
- 6.2.3 Zenoaq Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Zenoaq Pet Cancer Therapeutics Product Portfolio
- 6.2.5 Zenoaq Recent Developments
- 6.3 VetiVax
- 6.3.1 VetiVax Company Information
- 6.3.2 VetiVax Business Overview
- 6.3.3 VetiVax Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 VetiVax Pet Cancer Therapeutics Product Portfolio
- 6.3.5 VetiVax Recent Developments
- 6.4 VetDC, Inc
- 6.4.1 VetDC, Inc Company Information
- 6.4.2 VetDC, Inc Business Overview
- 6.4.3 VetDC, Inc Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 VetDC, Inc Pet Cancer Therapeutics Product Portfolio
- 6.4.5 VetDC, Inc Recent Developments
- 6.5 Rhizen Pharmaceutical SA
- 6.5.1 Rhizen Pharmaceutical SA Company Information
- 6.5.2 Rhizen Pharmaceutical SA Business Overview
- 6.5.3 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Product Portfolio
- 6.5.5 Rhizen Pharmaceutical SA Recent Developments
- 6.6 Regeneus Ltd.
- 6.6.1 Regeneus Ltd. Company Information
- 6.6.2 Regeneus Ltd. Business Overview
- 6.6.3 Regeneus Ltd. Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Regeneus Ltd. Pet Cancer Therapeutics Product Portfolio
- 6.6.5 Regeneus Ltd. Recent Developments
- 6.7 Oasmia Pharmaceuticals AB
- 6.7.1 Oasmia Pharmaceuticals AB Company Information
- 6.7.2 Oasmia Pharmaceuticals AB Business Overview
- 6.7.3 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Product Portfolio
- 6.7.5 Oasmia Pharmaceuticals AB Recent Developments
- 6.8 Ngelheim International GmbH
- 6.8.1 Ngelheim International GmbH Company Information
- 6.8.2 Ngelheim International GmbH Business Overview
- 6.8.3 Ngelheim International GmbH Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Ngelheim International GmbH Pet Cancer Therapeutics Product Portfolio
- 6.8.5 Ngelheim International GmbH Recent Developments
- 6.9 Morphogenesis, Inc
- 6.9.1 Morphogenesis, Inc Company Information
- 6.9.2 Morphogenesis, Inc Business Overview
- 6.9.3 Morphogenesis, Inc Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Morphogenesis, Inc Pet Cancer Therapeutics Product Portfolio
- 6.9.5 Morphogenesis, Inc Recent Developments
- 6.10 Merial Inc
- 6.10.1 Merial Inc Company Information
- 6.10.2 Merial Inc Business Overview
- 6.10.3 Merial Inc Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Merial Inc Pet Cancer Therapeutics Product Portfolio
- 6.10.5 Merial Inc Recent Developments
- 6.11 Karyopharm Therapeutics, Inc
- 6.11.1 Karyopharm Therapeutics, Inc Company Information
- 6.11.2 Karyopharm Therapeutics, Inc Business Overview
- 6.11.3 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Product Portfolio
- 6.11.5 Karyopharm Therapeutics, Inc Recent Developments
- 6.12 ELIAS Animal Health
- 6.12.1 ELIAS Animal Health Company Information
- 6.12.2 ELIAS Animal Health Business Overview
- 6.12.3 ELIAS Animal Health Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 ELIAS Animal Health Pet Cancer Therapeutics Product Portfolio
- 6.12.5 ELIAS Animal Health Recent Developments
- 6.13 Elanco
- 6.13.1 Elanco Company Information
- 6.13.2 Elanco Business Overview
- 6.13.3 Elanco Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Elanco Pet Cancer Therapeutics Product Portfolio
- 6.13.5 Elanco Recent Developments
- 6.14 Boehringer Ingelheim International GmbH
- 6.14.1 Boehringer Ingelheim International GmbH Company Information
- 6.14.2 Boehringer Ingelheim International GmbH Business Overview
- 6.14.3 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Product Portfolio
- 6.14.5 Boehringer Ingelheim International GmbH Recent Developments
- 6.15 Aratana Therapeutics, Inc
- 6.15.1 Aratana Therapeutics, Inc Company Information
- 6.15.2 Aratana Therapeutics, Inc Business Overview
- 6.15.3 Aratana Therapeutics, Inc Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Aratana Therapeutics, Inc Pet Cancer Therapeutics Product Portfolio
- 6.15.5 Aratana Therapeutics, Inc Recent Developments
- 6.16 AB Science
- 6.16.1 AB Science Company Information
- 6.16.2 AB Science Business Overview
- 6.16.3 AB Science Pet Cancer Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 AB Science Pet Cancer Therapeutics Product Portfolio
- 6.16.5 AB Science Recent Developments
7 North America
- 7.1 North America Pet Cancer Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Pet Cancer Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Pet Cancer Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Pet Cancer Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Pet Cancer Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Pet Cancer Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Pet Cancer Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Pet Cancer Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Pet Cancer Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Pet Cancer Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Pet Cancer Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Pet Cancer Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Pet Cancer Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Pet Cancer Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Pet Cancer Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst